Ultime notizie per Lazard (NYSE:LAZ) Azioni

Lazard

Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.

Long Ideas

News

Markets

Media

Trading Ideas

Laboratory Corporation Of America Holdings

PENN

UBER

L&#39;esperto del settore finanziario offre preziosi consigli su Uber e altre azioni, valutando potenzialità di crescita e investimenti sicuri.

Il consiglio dell&#39;esperto Jim Cramer su Uber e altri titoli

Lazard Inc

S.S. Lazio Fan Token

Luminar Technologies, Inc. - Class A Common Stock

Luminar Technologies Inc

Lazydays Holdings Inc Warrants (15/03/2023)

Wolfe Research analyst Brendan O'Brien downgrades Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) from Outperform to Peer Perform.

Downgrades

Analyst Ratings

Wolfe Research Downgrades Lazard to Peer Perform

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying more Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>).
On Jan. 2, JMP Securities analyst Andrew Boone downgraded Uber from Market Outperform to Market Perform and <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">maintained the price target of $95</a>.
The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) is a buy, Cramer said. &#8220;I think it's time to pick up that utility.&#8221;
On Dec. 6, AES increased its quarterly dividend from 17.25 cents to 17.595 cents per share.
Cramer said he doesn't like PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>).
On Dec. 13, JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $19 to $27.
When asked about Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>), Cramer said, &#8220;It's been very, very tough to own this great steel maker.&#8221;
On Dec. 16, the company provided fourth-quarter guidance, expecting EPS of 55 cents to 65 cents, versus the consensus of 86 cents.
Lazard, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) is &#8220;really inexpensive,&#8221; the &#8220;Mad Money&#8221; host said.
On Dec. 20, Keefe, Bruyette &amp; Woods analyst Aidan Hall downgraded Lazard from Outperform to Market Perform and lowered the price target from $65 to $57.
Cramer recommended to hold on to Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
On Dec. 20, the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
&#8220;I think the stock at 15 times earnings is fine,&#8221; Cramer said when asked about Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>). &#8220;The problem is its healthcare, and people do not like the healthcare stocks.&#8221;
On Dec. 17, Morgan Stanley analyst Ricky Goldwasser maintained Labcorp with an Overweight and raised the price target from $260 to $270.
Price Action:
<ul>
<li>Uber shares gained 4.7% to settle at $63.17 on Thursday.</li>
<li>AES shares rose 1.4% to close at $13.05 during the session.</li>
<li>Penn Entertainment shares fell 2.9% to settle at $19.24.</li>
<li>Lazard shares fell 1.4% to settle at $50.74 on Thursday.</li>
<li>Eli Lilly shares gained 0.8% to $778.07 on Thursday.</li>
<li>Nucor shares fell 1.9% to settle at $114.48 on Thursday.</li>
<li>Labcorp shares fell 0.5% to close at $228.19.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Acuity Brands Stock Ahead Of Q1 Earnings</a></li>
</ul>
Photo: Courtesy of <a href="https://www.flickr.com/photos/ojbyrne/" target="_blank" rel="noreferrer noopener">Owen Byrne</a> on flickr

Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>BMO Capital analyst Evan Seigerman downgraded the rating for Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Outperform to Market Perform and lowered the price target from $230 to $164. Biogen shares closed at $147.39 on Thursday. <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group analyst Cristina Fernandez downgraded NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Outperform to Market Perform and slashed the price target from $93 to $80. Nike shares closed at $77.10 on Thursday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Thomas Stephan downgraded the rating for RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) from Buy to Hold and lowered the price target from $65 to $40. RxSight shares closed at $38.19 on Thursday. <a href="https://www.benzinga.com/quote/RXST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Aidan Hall downgraded Lazard, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) from Outperform to Market Perform and cut the price target from $65 to $57. Lazard shares closed at $50.49 on Thursday. See how other analysts view this stock.</li>
<li>Citigroup analyst Thomas Palmer downgraded Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) from Buy to Neutral and lowered the price target from $90 to $68. Lamb Weston shares closed at $62.50 on Thursday. <a href="https://www.benzinga.com/quote/LW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NKE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="568" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184-1024x568.png" alt="" class="wp-image-701967" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184-1024x568.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

BIIB

RXST

This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Keefe, Bruyette &amp; Woods analyst Aidan Hall downgrades Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) from Outperform to Market Perform and lowers the price target from $65 to $57.

Price Target

Keefe, Bruyette & Woods Downgrades Lazard to Market Perform, Lowers Price Target to $57

Lazard CEO Orszag Says We Will Accomplish An Inflection Point On The Asset Side Of The Business In 2025

Lazard CEO Orszag Says We Will Move To An Environment In Which The Antitrust Authorities Will Not Have A Visceral Distaste For Big Tech; We Are Seeing A Lot Of Private Equity Activity Ramp Up; We Expect More Deal Making Activity Across The Board; Revenue, Shareholder Value Looking Very Positive For Lazard

Ratings for Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $57.86, a high estimate of $65.00, and a low estimate of $51.00. This current average has increased by 4.88% from the previous average price target of $55.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1733756416_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Lazard is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lazard. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lazard compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Lazard's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Lazard's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LAZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lazard analyst ratings.</a>
<h2>Delving into Lazard's Background</h2>
Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
<h3>Understanding the Numbers: Lazard's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Lazard's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 49.05%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 13.3%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Lazard's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 19.46%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Lazard's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.25%, the company showcases efficient use of assets and strong financial health.
Debt Management: Lazard's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.8, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Lazard Analyst Ratings: What You Need To Know

Morgan Stanley analyst Ryan Kenny downgrades Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) from Overweight to Equal-Weight and raises the price target from $60 to $63.

Morgan Stanley Downgrades Lazard to Equal-Weight, Raises Price Target to $63

Kenneth M. Jacobs Becomes Senior Chairman of the Firm
Richard D. Parsons Honored for Board Service
Lazard, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) today announced that <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lazard.com%2Four-people%2Fdan-schulman%2F&amp;esheet=54157314&amp;newsitemid=20241125060990&amp;lan=en-US&amp;anchor=Dan+Schulman&amp;index=1&amp;md5=9294548d22d082dcbbe72301bde1930a">Dan Schulman</a>, Board Member, has been appointed Lead Independent Director to succeed <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lazard.com%2Four-people%2Frichard-d-parsons%2F&amp;esheet=54157314&amp;newsitemid=20241125060990&amp;lan=en-US&amp;anchor=Richard+D.+Parsons&amp;index=2&amp;md5=7551326cfaedc7f2d975c528ec35a23c">Richard D. Parsons</a>, who remains on the Board, and that <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lazard.com%2Four-people%2Fpeter-r-orszag%2F&amp;esheet=54157314&amp;newsitemid=20241125060990&amp;lan=en-US&amp;anchor=Peter+R.+Orszag&amp;index=3&amp;md5=33bfe6ade736456635c0ba1bc89a1282">Peter R. Orszag</a>, Lazard CEO and Board Member, has been appointed Chairman of the Board, effective January 1, 2025.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lazard.com%2Four-people%2Fkenneth-jacobs%2F&amp;esheet=54157314&amp;newsitemid=20241125060990&amp;lan=en-US&amp;anchor=Kenneth+M.+Jacobs&amp;index=4&amp;md5=15c384676e8047d00a69bda405018059">Kenneth M. Jacobs</a>, Executive Chairman and Board Member, will become Senior Chairman of the Firm and Senior Advisor to the Board, and relinquish his board seat effective December 31, 2024. In his role as Senior Chairman, Mr. Jacobs will continue to advise many of the firm's most important clients and relationships globally.
These transitions represent a successful, multi-year succession planning process across Board and senior leadership at the firm.

Management

Lazard Appoints Peter R. Orszag As Chairman Of The Board; Kenneth M. Jacobs Becomes Senior Chairman Of The Firm

Analysts' ratings for Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $57.0, a high estimate of $65.00, and a low estimate of $51.00. Surpassing the previous average price target of $54.20, the current average has increased by 5.17%.
<img src="https://www.benzinga.com/files/images/story/2024/1730480424_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Lazard by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lazard. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Lazard compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Lazard's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Lazard's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LAZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lazard analyst ratings.</a>
<h2>Get to Know Lazard Better</h2>
Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
<h3>Lazard: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Lazard displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 6.72%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Lazard's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 7.05%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Lazard's ROE stands out, surpassing industry averages. With an impressive ROE of 11.52%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Lazard's ROA excels beyond industry benchmarks, reaching 1.08%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 5.18, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Lazard

Keefe, Bruyette &amp; Woods analyst Aidan Hall maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Outperform and raises the price target from $59 to $65.

Keefe, Bruyette & Woods Maintains Outperform on Lazard, Raises Price Target to $65

JMP Securities analyst Devin Ryan maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Market Outperform and raises the price target from $55 to $59.

JMP Securities Maintains Market Outperform on Lazard, Raises Price Target to $59

Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) reported quarterly earnings of $0.38 per share which missed the analyst consensus estimate of $0.40 by 5 percent. The company reported quarterly sales of $645.914 million which missed the analyst consensus estimate of $652.121 million by 0.95 percent. This is a 21.50 percent increase over sales of $531.617 million the same period last year.

Earnings

Earnings Misses

Lazard Q3 2024 Adj. EPS $0.38 Misses $0.40 Estimate, Sales $645.914M Miss $652.121M Estimate

WIIM

CARV

CZNB

EWBC

FCNCA

FFWM

FITB

FNWD

FULT

GBCI

HBAN

HOOD

HSBC

NYCB

SCHW

TIGR

TROW

TRUP

UPST

Shares of banking and financial services stocks are trading higher following better-than-expected financial results from JPMorgan Chase and Wells Fargo.

Preliminary average AUM for the quarter ended September 30, 2024 was $246.0 billion.&nbsp;

General

Lazar's Preliminary Assets Under Management As Of September 30, 2024 Totaled Approximately $247.7B, Including Market Appreciation Of $3B, Foreign Exchange Appreciation Of $1.5B And Net Outflows Of $1.3B

JMP Securities analyst Devin Ryan maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Market Outperform and raises the price target from $52 to $55.

JMP Securities Maintains Market Outperform on Lazard, Raises Price Target to $55

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $52.83, a high estimate of $60.00, and a low estimate of $42.00. Marking an increase of 7.82%, the current average surpasses the previous average price target of $49.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728406840_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Lazard among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lazard. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lazard compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Lazard's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Lazard's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LAZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lazard analyst ratings.</a>
<h2>Unveiling the Story Behind Lazard</h2>
Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
<h3>Lazard: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Lazard displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 6.72%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Lazard's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 7.05%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 11.52%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Lazard's ROA stands out, surpassing industry averages. With an impressive ROA of 1.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Lazard's debt-to-equity ratio stands notably higher than the industry average, reaching 5.18. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Lazard

UBS analyst Brennan Hawken maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Neutral and raises the price target from $49 to $52.

UBS Maintains Neutral on Lazard, Raises Price Target to $52

Morgan Stanley analyst Ryan Kenny maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Overweight and raises the price target from $56 to $60.

Morgan Stanley Maintains Overweight on Lazard, Raises Price Target to $60

5 analysts have expressed a variety of opinions on Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $51.8, a high estimate of $56.00, and a low estimate of $42.00. Observing a 4.65% increase, the current average has risen from the previous average price target of $49.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1726153224_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Lazard is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lazard. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lazard compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Lazard's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Lazard's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LAZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lazard analyst ratings.</a>
<h2>About Lazard</h2>
Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
<h3>Lazard: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Lazard's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 6.72%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Lazard's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 7.05%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Lazard's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.52%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.08%, the company showcases effective utilization of assets.
Debt Management: Lazard's debt-to-equity ratio surpasses industry norms, standing at 5.18. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Michael Brown of Wells Fargo maintained a Hold rating on Lazard (LAZ – Research Report), retaining the price target of $58.00. Michael Brow...

Lazard's Short-Term Challenges Overshadow Long-Term Optimism: Hold Rating Justified

In a report released today, Aidan Hall from KBW maintained a Buy rating on Lazard (LAZ – Research Report), with a price target of $65.00. The compa...

KBW Reaffirms Their Buy Rating on Lazard (LAZ)

Hello 2025, Here's What's In Store For Stocks After 2024

Tracking John Rogers' Ariel Investments Portfolio - Q3 2024 Update

Keefe Bruyette downgraded Lazard (LAZ) to Market Perform from Outperform with a price target of $57, down from $65. The firm says that despite rece...

Lazard downgraded to Market Perform from Outperform at Keefe Bruyette

Voya Large Cap Value Fund Q3 2024 Commentary

Wolfe Research downgraded Lazard (LAZ) to Peer Perform from Outperform without a price target as part of a 2025 playbook for the brokers, asset man...

Lazard downgraded to Peer Perform from Outperform at Wolfe Research

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: Biden blocks U.S. Steel buyout, Meta replaces chief policy exec

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Block upgraded, Bumble downgraded: Wall Street's top analyst calls

BAC, WFC, LPLA, HOOD, KKR, ARES: Wolfe's top picks for 2025

ACAD

ARES

BACRP

BMBL

BOKF

BPAQF

CHKP

CHWY

DNLI

ELEV

GNRC

GNTX

JBHT

KVUE

LPLA

MGRB

MGRD

MGRE

MSFT

MSGE

MSGS

MSTLW

NDAQ

NISTF

NPSCY

NTRS

NTRSO

NVST

REZI

SAEF

SPHR

SRZN

WFCNP

ZBRA

Press Releases

Lazard Chief Executive Officer Peter R. Orszag to Speak at the 2024 Goldman Sachs U.S. Financial Services Conference

Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in October

Lazard Appoints Dan Schulman as Lead Independent Director and Peter R. Orszag as Chairman of the Board

Lazard, Inc. Commences Consent Solicitation and Offer to Guarantee for Lazard Group LLC Senior Notes

Lazard Reports November 2024 Assets Under Management

Lazard, Inc. Announces Results of Consent Solicitation and Offer to Guarantee Lazard Group LLC Senior Notes

KBW Announces Index Rebalancing for Fourth-Quarter 2024

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Lazard, Inc. (NYSE: LAZ)

Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in November

Lazard Global Total Return and Income Fund Announces Monthly Distribution Amount

Comments

Lazard

Notizie

Ultime notizie per Lazard (NYSE:LAZ) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO